Aug-24-20 Initiated
SVB Leerink
Outperform
$41
Aug-24-20 Initiated
Morgan Stanley
Overweight
$49
Aug-24-20 Initiated
JP Morgan
Overweight
$50
Feb-17-21 07:30AM
Feb-11-21 04:00PM
07:00AM
Jan-11-21 01:52PM
Jan-04-21 07:30AM
Dec-28-20 11:21PM
Dec-17-20 07:30AM
Dec-11-20 12:54PM
Dec-10-20 01:03PM
Dec-07-20 04:30PM
Dec-05-20 11:00AM
Nov-24-20 07:30AM
Nov-10-20 07:00AM
Nov-04-20 01:33PM
Oct-30-20 06:52AM
Oct-21-20 07:30AM
Sep-21-20 06:14AM
Sep-17-20 09:49AM
Sep-08-20 04:15PM
Sep-02-20 07:30AM
Aug-25-20 07:30AM
Aug-03-20 04:30PM
Jul-30-20 08:53AM
07:32AM
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
VAN BEEK JEROEN B Chief Commercial Officer Feb 23 Sale 39.56 2,118 83,783 494,162 Feb 23 07:44 PM Vera Juan Director Feb 23 Sale 39.40 8,850 348,684 2,403,764 Feb 23 07:44 PM Leen Ann M. Chief Scientific Officer Feb 23 Sale 39.50 4,199 165,876 2,471,685 Feb 23 07:43 PM Brenner Malcolm Director Feb 23 Sale 39.47 8,489 335,036 968,619 Feb 23 07:42 PM VAN BEEK JEROEN B Chief Commercial Officer Feb 22 Sale 42.54 2,800 119,118 496,280 Feb 23 07:44 PM Vera Juan Director Feb 22 Sale 42.57 14,321 609,614 2,412,614 Feb 23 07:44 PM Leen Ann M. Chief Scientific Officer Feb 22 Sale 42.57 5,706 242,880 2,475,884 Feb 23 07:43 PM Brenner Malcolm Director Feb 22 Sale 42.57 11,423 486,246 977,108 Feb 23 07:42 PM Hagen Brett R Chief Accounting Officer Feb 22 Sale 43.14 800 34,509 64,765 Feb 23 07:43 PM VAN BEEK JEROEN B Chief Commercial Officer Feb 19 Sale 41.71 4,165 173,720 499,080 Feb 23 07:44 PM Vera Juan Director Feb 19 Sale 41.79 13,233 553,011 2,426,935 Feb 23 07:44 PM Leen Ann M. Chief Scientific Officer Feb 19 Sale 41.75 7,541 314,868 2,481,590 Feb 23 07:43 PM Brenner Malcolm Director Feb 19 Sale 41.78 11,990 500,935 988,531 Feb 23 07:42 PM Bornstein Jeffrey S Director Feb 18 Sale 40.43 20,583 832,119 0 Feb 23 07:57 PM Hagen Brett R Chief Accounting Officer Feb 18 Sale 40.11 741 29,724 65,565 Feb 19 08:44 AM Leen Ann M. Chief Scientific Officer Feb 18 Sale 40.81 2,700 110,194 2,489,131 Feb 19 08:44 AM Vera Juan Director Feb 18 Sale 40.75 8,942 364,368 2,440,168 Feb 19 08:41 AM VAN BEEK JEROEN B Chief Commercial Officer Feb 18 Sale 40.67 2,085 84,787 503,245 Feb 19 08:41 AM Brenner Malcolm Director Feb 18 Sale 40.75 6,757 275,366 1,000,521 Feb 19 08:38 AM Vera Juan Director Feb 17 Sale 40.34 7,460 300,930 2,449,110 Feb 18 09:25 PM Brenner Malcolm Director Feb 17 Sale 40.45 5,165 208,925 1,007,278 Feb 18 09:24 PM Leen Ann M. Chief Scientific Officer Feb 17 Sale 40.45 2,286 92,468 2,491,831 Feb 18 09:22 PM VAN BEEK JEROEN B Chief Commercial Officer Feb 17 Sale 40.36 2,300 92,837 505,330 Feb 18 09:20 PM Hagen Brett R Chief Accounting Officer Feb 17 Sale 40.42 2,320 93,763 66,306 Feb 18 09:18 PM Vera Juan Director Feb 16 Sale 41.86 10,400 435,365 2,456,570 Feb 18 09:25 PM Brenner Malcolm Director Feb 16 Sale 41.85 6,220 260,332 1,012,443 Feb 18 09:24 PM Leen Ann M. Chief Scientific Officer Feb 16 Sale 41.88 3,050 127,733 2,494,117 Feb 18 09:22 PM VAN BEEK JEROEN B Chief Commercial Officer Feb 16 Sale 41.86 3,100 129,770 507,630 Feb 18 09:20 PM Hagen Brett R Chief Accounting Officer Feb 16 Sale 41.91 3,050 127,816 68,626 Feb 18 09:18 PM Melian Agustin Chief Medical Officer Feb 02 Sale 41.19 54,849 2,259,230 520,266 Feb 04 04:35 PM VAN BEEK JEROEN B Chief Commercial Officer Feb 02 Sale 41.19 48,910 2,014,603 510,730 Feb 04 04:35 PM Jovan-Embiricos Morana Director Aug 03 Buy 17.00 2,900,000 49,300,000 2,800,000 Aug 06 06:06 AM VAN BEEK JEROEN B Chief Commercial Officer Aug 03 Buy 17.00 3,000 51,000 524,640 Aug 05 09:55 PM Brainard Diana Director Aug 03 Buy 17.00 6,300 107,100 6,300 Aug 05 09:42 PM Atillasoy Ercem See Remarks Aug 03 Buy 17.00 3,500 59,500 78,500 Aug 05 09:39 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite